Parabilis Medicines, Inc. Common Stock Earnings Dividend

Parabilis Medicines, Inc. Common Stock’s revenue jumped +Inf% since last year same period to $0.15Mn in the Q2 2026. On a quarterly growth basis, Parabilis Medicines, Inc. Common Stock has generated +Inf% jump in its revenue since last 3-months.

Parabilis Medicines, Inc. Common Stock’s net profit fell -50.71% since last year same period to $-52.46Mn in the Q2 2026. On a quarterly growth basis, Parabilis Medicines, Inc. Common Stock has generated -15.77% fall in its net profits since last 3-months.

Parabilis Medicines, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -35447.97% in the Q2 2026. On a quarterly growth basis, Parabilis Medicines, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.

Parabilis Medicines, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.16.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Parabilis Medicines, Inc. Common Stock’s return on assets (ROA) stands at 0.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Parabilis Medicines, Inc. Common Stock’s return on equity (ROE) stands at 0.